Business UpdateApr 16, 2026, 07:32 AM
Korro Bio to Present OPERA® RNA Editing Data at 4 Conferences
AI Summary
Korro Bio, Inc. announced upcoming oral and poster presentations highlighting data from its oligonucleotide delivery based RNA editing technology (OPERA®) at four scientific conferences in April and May 2026. The presentations will cover preclinical data for KRRO-121 in hyperammonemia, RNA editing for Alpha-1 Antitrypsin Deficiency models, and advancements in the OPERA® platform capabilities. These presentations underscore the company's progress in developing genetic medicines for various diseases.
Key Highlights
- Korro Bio to present data from its OPERA® RNA editing technology at 4 conferences.
- Oral presentations include preclinical data for KRRO-121 in hyperammonemia.
- Data on RNA editing for Alpha-1 Antitrypsin Deficiency models will be presented.
- Poster presentations will cover ALS disease models and OPERA® platform innovations.
- Conferences include ASGCT, TIDES USA, and EASL Congress in April and May 2026.
Price Impact
More from KRRO